CSI Market
Sign In | Register

Biora Therapeutics Inc (BIOR) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access BIOR Annual Cash Flow →
Reviewing cash flow figures over time highlights how Biora Therapeutics Inc balances operational cash generation with investment and financing decisions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Sep 30 2024) (Jun 30 2024) (Mar 31 2024) (Dec 31 2023)
Operating Activities
Income-24.91
Depreciation & amortization0.05
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Asset Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation1.38
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Non Cash Revenue Reserve-
Loss On Extinguishment Of Convertible Notes And Accrued Interest-3.82
Induced Conversion Of Convertible Debt Expense-
Income taxes0.00
Gain (Loss) on Investments0.00
Increase (Decrease) in Income Taxes Receivable3.29
Increase (Decrease) in Accounts Payable0.65
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-0.10
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.59
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities36.41
Discontinued operations0.00
Net Cash flow from Operating Activities17.37
Investing Activities
Capital Expenditures-17.12
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Proceeds From Sale Of Equity Securities Fv Ni3.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-17.12
Financing Activities
Short-term debt Net0.41
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-0.11
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock10.63
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net-0.07
Other net0.00
Principal Payments On Capital Lease Obligations-
Payments For Financing Of Insurance Premiums-
Payment For Deferred Offering Costs-
Payments Of Deferred Offering Costs-
Payments For Insurance Financing-1.53
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents15.21
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities10.87
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow0.25
Total Cash Flow11.11
4 historic quarters locked

Sign in to unlock the full Biora Therapeutics Inc cash flow history.

Sign In Create Free Account

About Biora Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20240930)
  • Filed with the SEC: November 14, 2024
  • Source: bior-20240930.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000950170-24-127060

Figures are derived from filed reports and may be restated. Historical data is subject to revision.